ArticleFrontiers in pharmacology2025
Animal-derived ingredients in medicines: a framework for ethical prescribing practices.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Porcine-derived materials in urology Practical ethical guidance for caring for Muslim and Jewish patients.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026Review
- Understanding Biologics in CRSwNP: Related Events and Insights.Current allergy and asthma reports · 2026Review
- Beyond Side Effect: Immuno-Ethical Risk Analysis of Animal-Derived Ingredients in Pharmaceuticals.Risk management and healthcare policy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An increasing number of patients want to avoid animal-derived ingredients in medications due to ethical, religious, or cultural beliefs, yet transparency about these ingredients remains limited. Healthcare professionals often lack guidance on how to respect their preferences while ensuring effective treatment. Here, we propose an ethical pharmacotherapy modification framework that guides clinicians through a stepwise approach, altering manufacturer, dosage form, administration method, or medication itself, to accommodate patient values without compromising clinical efficacy. This framework balances respect for patient autonomy with clinical beneficence. Implementing this approach is likely to enhance patient trust and adherence by aligning pharmaceutical care with individual ethical considerations and promoting patient-centered care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.